Europe, World, Dec. 1 -- Fizer Inc and BioNTech have applied to the European drugs regulator for conditional authorization of their COVID-19 vaccine, according to sources, following similar steps in the United States and Britain, the companies said on Tuesday.
The application came weeks after the drug maker projected promising result in phase 3 trial of its COVID-19 vaccine, sharing joy over a 90 percent victory in the war against growing respiratory illness.
The company has previously sought the United States on Nov. 20, taking them a step closer to launching their vaccine for public use.
In their pursuit of a European launch, potentially this year, the partners are neck-and-neck with rival Moderna, which said on Monday it would ask the...